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Abstract Osteoblastic cells have been shown to be involved in 
osteoclast formation through cell to cell contacts. This study was 
designed to examine the possible function of vascular cell 
adhesion molecule 1 (VCAM-1) during osteoclastogenesis. As a 
source for stromal cells we used the recently established mouse 
bone marrow stromal cell line mBMS-Bl which has the ability to 
support osteoclastogenesis when used in co-culture with a crude 
spleen cell suspension. mBMS-Bl cells express a single ~ 3.9 kb 
VCAM-1 mRNA species. Expression was low under basal 
culture conditions and a 5-10-fold increase was observed in the 
presence of l ,25(OH)2D3 . Cell surface expression of VCAM-1 
examined by FACS analysis was increased about 2-fold after 
l ,25(OH) 2 D 3 treatment. Immunoprecipitation of cell surface 
expressed VCAM-1 or total VCAM-1 protein using the anti-
VCAM-1 monoclonal antibody MK2.7 resulted in a single ~ 110 
kDa protein on SDS-PAGE. Induction by l ,25(OH) 2 D 3 was 
about 2-5-fold on day 3. The stromal cell-osteoclast precursor 
cell interaction was investigated in a co-culture of the mBMS-Bl 
and mouse spleen cells in the presence of l ,25(OH)2D3 . The 
monoclonal antibody MK2.7 which is known to block hemopoie-
tic-stromal cell recognition inhibited the formation of osteoclasts 
when added to the co-culture at day 2 but not day 4. These data 
suggest that VCAM-1 is involved in the interaction between 
stromal cells and osteoclastic precursor cells during osteoclasto-
genesis presumably most important during early stages of the 
formation of osteoclasts. 
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1. Introduction 
During the development of osteoclasts, the osteoclast pre-
cursor cells are considered to interact closely with osteoblasts 
and/or stromal cells [1]. In a co-culture system between mouse 
spleen cells and a mouse osteoblastic cell line, cell to cell 
contacts were shown to be involved in osteoclastogenesis 
and the osteoblastic cell line could be replaced by stromal 
cell lines derived from bone marrow [2,3]. Cell adhesion mol-
ecules on stromal cells could be important for the release of 
cytokines as well as for mediating undifferentiated bone mar-
row cell binding. Recently, it has been shown that LFA-1 and 
ICAM-1 interactions are involved in tumours in the formation 
of multinucleated giant cells (MGC) which like osteoclasts are 
formed through the differentiation and fusion of progenitors 
[4]. Fur ther studies indicated that LFA-1 and ICAM-1 may 
play a role in osteoclast development via interaction between 
stromal cell and osteoclast progenitors as well as among os-
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teoclast progenitors [5]. ICAM-1 and VCAM-1 are also ex-
pressed on osteoblasts and crosslinking of these adhesion mol-
ecules on the osteoblast's cell surface induced IL-6 secretion 
from the osteoblasts [6]. In the present study we wanted to 
investigate the impact of VCAM-1 expression on stromal cells 
during osteoclastogenesis using a co-culture system between 
the recently established murine stromal cell line mBMS-Bl [7] 
and murine spleen cells. VCAM-1 was first identified as an 
adhesion molecule inducible on endothelial cells by inflamma-
tory cytokines such as IL-1 , tumour necrosis factor and lip-
opolysaccharide and it stays stably expressed at the cell sur-
face for more than 48 h after induction. The molecule binds to 
a variety of leukocytes, including B-cells, T-cells, basophils, 
eosinophils, monocytes and lymphocyte precursors. VCAM-1 
belongs to the Ig superfamily and several splice variants have 
been described whereas the major form in humans contains 
seven Ig domains of which domains 1-3 are homologous to 
domains 4-6 [8,9]. The binding partner of VCAM-1 is the ßi 
integrin VLA-4 which is found on all leukocytes except neu-
trophils [10,11]. As l ,25(OH)2D3 is necessary for the develop-
ment of osteoclasts in our co-culture system we also investi-
gated the influence of l ,25(OH) 2 D 3 on VCAM-1 expression in 
the mBMS-Bl stromal cells. 
2. Materials and methods 
2.1. Cell culture 
mBMS-Bl cells were cultured in DMEM/Ham's F12 (1:1) supple-
mented with 100 U/ml of benzylpenicillin, 100 Ug/ml streptomycin and 
10% (v/v) FCS at 33°C [7]. 
2.2. Immunoprecipitation 
mBMS-Bl cells (3xl0 6 ) were labelled for 4 h with 200 uCi of 
[35S]methionine in 1 ml of methionine-free MEM. The labelling me-
dium was added to the cells 1 h before addition of the radioactive 
amino acid. Immunoprecipitations were done as described [7]. 
For cell surface immunoprecipitations, 3 X 106 radioactively labelled 
mBMS-Bl was washed in ice-cold PBS and incubated in the culture 
dish for 45 min at 4°C with the mAb MK2.7 (50 ug/ml). Antibodies 
were washed away by rinsing the culture dish three times with PBS. 
Cells were scraped off the plate with a rubber policeman, and the 
pelleted cells were lysed in 1 ml of lysis buffer (50 mM Tris-HCl, 
pH 7.4; 150 mM NaCl; 1 mM phenylmethylsulfonyl fluoride; 0.5% 
Triton X-100). The lysis buffer already contained the extracted cell 
proteins of a 10-fold excess of unlabelled mBMS-Bl cells. Further 
immunoprecipitation was carried out as usual. 
2.3. Flow cy tome try 
Cells were grown to confluence and incubated with 10~8 M 
l,25(OH)2D3 for the periods indicated in the figure. Cells were de-
tached with 10 mM EDTA/PBS and reacted with the anti-VCAM-1 
antibody MK2.7 and MK1.9 [12]. After 1 h incubation at 4°C, cells 
were washed and incubated with the anti-rat fluorescinisothiocyanate 
(FITC)-conjugated second antibody. Background staining was as-
sessed in the presence of the second antibody only. Five thousand 
viable cells were analyzed with a FACscan (Becton Dickinson). 
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2.4. RNA blot-hybridization (Northern) analysis 
Total RNA was prepared and analyzed by hybridization to the 32P-
labelled murine VCAM-1 DNA probe using standard procedures [13]. 
2.5. Bone resorption-Pit assay 
Dentine slices (4X4 mm, thickness 130-180 mm) were prepared 
with a low-speed diamond saw (Buehler, Illionis, USA), sterilized 
with ethanol and kept in culture medium for at least 2 h prior to 
use. Stromal cells were seeded in 48-well plates on the dentine slices 
and grown to confluence. After 2 days at 39°C, 5 X 105 a crude spleen 
cell suspension, prepared from 8-14-day-old mice, was added per well. 
Culture was continued in the presence of l,25(OH)2D3 (10~
8 M) and 
dexamethasone (10~7 M) for further 12 days. At the end of the culture 
period, the slices were washed twice with distilled water and the cells 
were removed from the slices by rubbing with a silicon rubber stop. 
The slices were etched in 5% (w/v) aluminum sulfate for 10 min, rinsed 
with distilled water, stained with Coomassie brilliant blue (0.5% CBB 
in 45% (v/v) methanol, 9% (v/v) acetic acid) for 2 min, rinsed in water 
and embedded. Resorbed area was quantified using a Leitz Quantimet 
image analysis system and expressed as mm2 resorbed area per cm2. 
3. Results and discussion 
The expression of the cell adhesion molecule VCAM-1 by 
the stromal cell line mBMS-Bl was first examined by FACS 
analysis. mBMS-Bl cells clearly show a basal expression of 
VCAM-1 as they react with the anti-VCAM-1 mAb MK2.7 
(Fig. 1). In the same experiment the influence of l,25(OH)2D3 
on the VCAM-1 expression was investigated. Cells were 
grown to confluence at 33°C and further cultured in the pres-
ence or absence of l,25(OH)2D3 at 37°C. In the presence of 
1(T8 M l,25(OH)2D3 VCAM-1 is up-regulated about 1.5-2-
Fig. 1. Cell surface expression of the cell adhesion molecule 
VCAM-1. Clone mBMS-Bl was grown to confluence and treated 
with or without 10"8 M l,25(OH)2D3 (-D3 or +D3) at 37°C for 
the time period indicated. Thereafter cells were processed for FACS 
analysis using the anti-VCAM-1 mAb MK2.7. The mean value of 
the fluorescence are indicated. Ctrl.: cells incubated with second 
antibody only. A representative experiment of two different determi-
nations is shown. 
Fig. 2. Induction of VCAM-1 mRNA by l,25(OH)2D3. mBMS-Bl 
cells were grown to confluence (day 0) at 33°C or further cultured 
at 37°C for 2, 4, 6 or 8 days in the presence or absence of 
l,25(OH)2D3 (D3). Thereafter total RNA was extracted and 15 ug 
loaded per lane. The cDNA probe used for hybridization was mu-
rine VCAM-1. A representative experiment of two different determi-
nations is shown. 
fold and the induction sustains during the entire observation 
period of 8 days. 
To clarify if the up-regulation of VCAM-1 by l,25(OH)2D3 
takes place at the level of transcription or translation we car-
ried out Northern blot analysis (Fig. 2). mBMS-Bl cells were 
grown to confluence at 33°C and further cultured in the pres-
ence or absence of l,25(OH)2D3 at 37°C for the times indi-
cated in the figure. Northern blot analysis of total mRNA 
using a murine VCAM-1 probe showed a single ~3.9 kb 
VCAM-1-specific mRNA species. The basal expression of 
the VCAM-1 mRNA seems to be very low and is not induced 
after postconfluent growth of the mBMS-Bl cells. Treatment 
of the mBMS-Bl cells with l,25(OH)2D3 dramatically enhan-
ces the expression of VCAM-1 mRNA indicating that the 
induction mainly takes place on the transcriptional level. 
Quantitative analysis using a Phosphorlmager shows that 
the increase in steady-state mRNA is about 5-10-fold (data 
not shown). The increase is sustained during the entire obser-
vation period of 8 days. These results demonstrate the absence 
of VCAM-1 splice variants in the mBMS-Bl cells which had 
been described in other cell lines [8,9,14,15]. In the mouse a 
glycolipid-anchored, truncated splice variant of VCAM-1 
comprising only the first three Ig domains has been reported 
[16,17]. 
Next we investigated the VCAM-1 expression on protein 
level (Fig. 3). Immunoprecipitation of cell surface-expressed 
VCAM-1 or total VCAM-1 protein using the anti-VCAM-1 
monoclonal antibody (mAb) MK2.7 resulted in a single — 110 
kDa protein on SDS-PAGE. Quantivative analysis of the 
bands using a Posphorlmager indicated that the induction 
of VCAM-1 by l,25(OH)2D3 was about 3-5-fold on protein 
level (data not shown). The elevated expression of VCAM-1 
after l,25(OH)2D3 treatment was visible in both cases, namely 
after precipitation of VCAM-1 from total cell lysate (compare 
lanes 1 and 2) and in the cell surface expressed VCAM-1 
fraction (compare lanes 3 and 4). In line with the results 
gained from the Northern blot analysis no truncated splice 
variant of VCAM-1 could be detected. Furthermore, no gly-
cosylated variants of VCAM-1 which had been described for 
the glycolipid anchored VCAM-1 in mouse endothelioma cells 
[14] seem to be present in the mBMS-Bl cells. 
Finally we were interested in the functional impact of the 
VCAM-1 expression and VCAM-1 inducibility on osteoclas-
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Fig. 3. Induction of VCAM-1 by l,25(OH)2D3 on protein level. mBMS-Bl cells were grown to confluence at 33°C and incubated for 3 days at 
37°C in the presence or absence of 10~8 M l,25(OH)2D3 (D3). Thereafter cells were labelled for 4 h with [
35S]methionine and either detergent 
extract (lanes 1 and 2) or intact cells (lanes 3 and 4) were incubated with mAb MK2.7. For cell surface irnmunoprecipitations intact cells were 
washed after antibody incubation and lysed in detergent buffer containing a 10-fold excess of unlabelled mBMS-Bl cellular protein. Antigen 
antibody complexes were pelleted with protein G-Sepharose and separated on a 10% polyacrylamide gel. A representative experiment of two 
different determinations is shown. 
togenesis. We have recently demonstrated that the mBMS-Bl 
cells have the ability to support the induction of osteoclasts 
from a crude spleen cell population using co-culture experi-
ments [7]. This osteoclast inductive capacity was only ob-
served at the non-permissive temperature for cellular growth 
at 39°C and in the presence of 1(T8 M l,25(OH)2D3. To 
examine the influence of VCAM-1 on osteoclastogenesis we 
carried out co-culture experiments in the presence or absence 
of the VCAM-1 specific mAb MK2.7 which blocks the inter-
action between VCAM-1 and its ligand (Fig. 4). At the end of 
the culture, bone resorption pits were identified on the dentine 
slices as a measurement for the number of osteoclasts formed. 
Formation of osteoclasts from the precursor cells is dose-de-
pendently inhibited by mAb 2.7. The mAb MK1.9 which 
binds to VCAM-1 but does not block the interaction with 
the ligand does not significantly influence osteoclastogenesis. 
Furthermore, when the blocking mAb MK2.7 was added at 
day 4 of co-culture, influence on the osteoclast formation 
could no longer be observed. 
First, these data clearly indicate that a cell to cell contact 
between the stromal cell line mBMS-Bl and the osteoclast 
precursor cells is necessary for osteoclastogenesis. The cell 
adhesion molecule VCAM-1 expressed on the stromal cell 
and the corresponding ligand on the osteoclast precursor 
cell are crucial for osteoclast formation. The induction of 
VCAM-1 upon the addition of l,25(OH)2D3 might improve 
the interactions between both cell types in the co-culture. It is 
well established that in several co-culture systems the addition 
of l,25(OH)2D3 is absolutely required for the formation of 
osteoclasts [2,7]. Therefore, further factors induced by 
l,25(OH)2D3 might be involved in osteoclastogenesis. The 
interaction of VCAM-1 with its ligand on the osteoclast pre-
cursor cells might, in addition to the function as a glue to the 
opposing partner, transduce activation signals in the stromal 
cells which facilitate the production of factors stimulating 
osteoclastogenesis, a concept which has recently been de-
scribed [6]. 
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Fig. 4. Blocking anti VCAM-1 antibody inhibit osteoclast formation 
in the co-culture system. Stromal cells were seeded in 48-well plates 
on the dentine slices and grown to confluence at 33°C. After 2 days 
at 39°C, 5 X105 mouse spleen cells were added per well. Culture 
was continued at 39°C in the presence or absence of the mAb for 
further 10 days. Antibody solutions were purified hybridoma super-
natant 1:10 or 1:120 diluted. Data are shown as mean±SD of at 
least four different determinations. Experiments were performed 
three times with similar results. *P<0.01 compared with corre-
sponding non-mAb-treated group. 
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Second, the interaction between VCAM-1 and its ligand on 
the osteoclast precursor is necessary during the early stages of 
osteoclast formation. It is generally assumed that during this 
early stage of osteoclast formation the osteoclast precursor 
cells proliferate and differentiate into mononuclear preosteo-
clasts before they fuse to the multinucleated mature osteo-
clasts [18-20]. Our results indicate that during this initial 
phase the binding of VCAM-1 to the preosteoclast is one of 
the necessary factors for osteoclastogenesis to proceed. 
The ligand for VCAM-1 on the osteoclast precursor cells 
could be VLA-4 which belongs to the ßi integrin subfamily of 
adhesion molecules. VLA-4 mediated interaction with its li-
gands has been shown to be essential for several physiologic 
processes such as lymphopoiesis [12], myogenesis and leuko-
cyte extravasation to the sites of inflammation [21]. In this 
context it is interesting that VCAM-1 expression has been 
found on stromal cells of the bone marrow where it mediates 
binding to lymphocytes precursors [22], osteoclast precursors 
[23] and to CD34 h l hematopoietic stem cells [24] indicating 
that this adhesion pathway is of general importance during 
bone marrow stem cell differentiation. 
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